Jill DeSimone joins Swim Across America’s board of directors

Data from Gardasil 9 studies reinforce importance of gender-neutral HPV vaccination in adults

Clinical and real-world data for the 9-valent human papillomavirus vaccine, Gardasil 9, evaluating the burden and incidence of certain HPV-related cancers and diseases, were presented at the International Papillomavirus Conference 2024 in Edinburgh, UK, from Nov. 12-15.

November 15, 2024

Vol.50 No.43

In Brief

Merck acquires Modifi Biosciences

Modifi Biosciences Inc., a Yale University spinout company formed in 2021 that develops direct DNA-modification-enabled cancer therapeutics, has been acquired by Merck.

October 25, 2024

Vol.50 No.40

Regulatory News

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitors
Vote may lead to rollback of some indications held by BMS and Merck

The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated as a first-line treatment for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.

Qure.ai completes $65M Series D funding round

Qure.ai has announced the completion of a $65 million Series D funding round. The investment will expedite expansion into the U.S. market and other countries, increase investment in foundational AI models, and enable complementary med-tech company acquisitions.

October 04, 2024

Vol.50 No.37

Guest Editorial

Group chairs propose funding strategy to jump-start correlative studies

The National Academy of Medicine recognized the value of correlative science in publicly funded clinical trials in 2010, recommending “the incorporation of innovative science into cancer clinical trials through the support and use of biorepositories.”

September 20, 2024

Vol.50 No.35

By Peter J. O'Dwyer

Funding Opportunities

DOD Glioblastoma Research Program funding opportunities for FY24

The FY24 Defense Appropriations Act provides funding for the Glioblastoma Research Program to support research of high potential impact and exceptional scientific merit to reduce the burden of glioblastoma on service members and their families, veterans, and the American public. The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command.

September 20, 2024

Vol.50 No.35

Jill DeSimone joins Swim Across America’s board of directors

YOU MAY BE INTERESTED IN

Data from Gardasil 9 studies reinforce importance of gender-neutral HPV vaccination in adults

Merck acquires Modifi Biosciences

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitors
Vote may lead to rollback of some indications held by BMS and Merck

Qure.ai completes $65M Series D funding round

Group chairs propose funding strategy to jump-start correlative studies

DOD Glioblastoma Research Program funding opportunities for FY24

Renew today!

Subscriber content

Login

Jill DeSimone joins Swim Across America’s board of directors

YOU MAY BE INTERESTED IN

Data from Gardasil 9 studies reinforce importance of gender-neutral HPV vaccination in adults

Merck acquires Modifi Biosciences

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitorsVote may lead to rollback of some indications held by BMS and Merck

Qure.ai completes $65M Series D funding round

Group chairs propose funding strategy to jump-start correlative studies

DOD Glioblastoma Research Program funding opportunities for FY24

Login

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitors
Vote may lead to rollback of some indications held by BMS and Merck